Signaturefd LLC Purchases 1,069 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Signaturefd LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 144.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,809 shares of the company’s stock after purchasing an additional 1,069 shares during the period. Signaturefd LLC’s holdings in CRISPR Therapeutics were worth $114,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors lifted its stake in shares of CRISPR Therapeutics by 3.2% in the 1st quarter. Arkadios Wealth Advisors now owns 13,224 shares of the company’s stock valued at $830,000 after acquiring an additional 404 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of CRISPR Therapeutics by 38.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 1,913 shares of the company’s stock valued at $120,000 after acquiring an additional 530 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management lifted its stake in shares of CRISPR Therapeutics by 3.8% in the 1st quarter. B & T Capital Management DBA Alpha Capital Management now owns 23,324 shares of the company’s stock valued at $1,464,000 after acquiring an additional 852 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its stake in shares of CRISPR Therapeutics by 9.4% in the 1st quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 5,770 shares of the company’s stock valued at $362,000 after acquiring an additional 498 shares during the last quarter. Finally, Seaview Investment Managers LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at about $276,000. Institutional investors own 56.12% of the company’s stock.

CRISPR Therapeutics Stock Up 0.8 %

CRISPR Therapeutics stock opened at $77.12 on Wednesday. The company has a market capitalization of $5.97 billion, a P/E ratio of 21.36 and a beta of 1.91. The stock’s 50 day moving average is $67.11 and its 200 day moving average is $62.56. CRISPR Therapeutics AG has a twelve month low of $42.51 and a twelve month high of $142.64.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last issued its earnings results on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.91) by ($0.41). CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. The business had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $2.45 million. During the same quarter in the prior year, the business posted ($1.51) earnings per share. The business’s revenue for the quarter was up 74.4% on a year-over-year basis. As a group, equities analysts expect that CRISPR Therapeutics AG will post -8.98 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $61.59, for a total transaction of $1,539,750.00. Following the sale, the chief executive officer now directly owns 290,279 shares in the company, valued at approximately $17,878,283.61. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.70% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of recent analyst reports. Chardan Capital lowered their price target on CRISPR Therapeutics from $168.00 to $164.00 and set a “buy” rating for the company in a research report on Wednesday, June 22nd. Credit Suisse Group initiated coverage on CRISPR Therapeutics in a research report on Thursday, April 28th. They set a “neutral” rating and a $78.00 price target for the company. BMO Capital Markets initiated coverage on CRISPR Therapeutics in a research report on Thursday, June 16th. They set an “outperform” rating and a $98.00 price target for the company. Barclays lowered their price target on CRISPR Therapeutics from $107.00 to $99.00 in a research report on Tuesday, May 10th. Finally, Piper Sandler upped their price target on CRISPR Therapeutics from $115.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday, June 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $114.31.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

See Also

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Want More Great Investing Ideas?

Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Read more here: Source link